Upstream Bio (NASDAQ:UPB) Sets New 52-Week High – Still a Buy?

Upstream Bio, Inc. (NASDAQ:UPB) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $33.28 and last traded at $32.5990, with a volume of 46309 shares. The stock had previously closed at $32.60.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on UPB shares. Evercore ISI began coverage on shares of Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target for the company. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. Truist Financial started coverage on Upstream Bio in a report on Tuesday, October 14th. They issued a “buy” rating and a $47.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, October 8th. Finally, Lifesci Capital initiated coverage on Upstream Bio in a report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $45.25.

Upstream Bio Price Performance

The company has a 50 day simple moving average of $27.66 and a 200-day simple moving average of $20.87. The stock has a market cap of $1.68 billion, a P/E ratio of -16.49 and a beta of 1.90.

Upstream Bio (NASDAQ:UPB) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.15. The firm had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.65 million. Upstream Bio had a negative return on equity of 28.71% and a negative net margin of 4,366.77%. As a group, research analysts expect that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently made changes to their positions in the business. Russell Investments Group Ltd. raised its position in Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc lifted its stake in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares during the last quarter. CWM LLC boosted its holdings in Upstream Bio by 107.5% during the 2nd quarter. CWM LLC now owns 3,312 shares of the company’s stock valued at $36,000 after acquiring an additional 1,716 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its holdings in Upstream Bio by 95.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock valued at $39,000 after acquiring an additional 1,736 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.